Here's a development in the ongoing saga of prescription drug prices: two more pharmaceutical heavyweights are reportedly jumping into the TrumpRx initiative. Amgen Inc. (AMGN) and GSK plc (GSK) are set to announce a partnership with the TrumpRx.gov platform, according to a report, a move that will bring some substantial discounts on specific medications to the website.

Think of it as the drug discount club adding more members. This collaboration will reportedly boost the total number of discounted prescription medications available on the platform to 54, sourced from five different pharmaceutical companies. It's a notable expansion for a program that's been a focal point in the political and economic debate over healthcare costs.

So, what's actually going to get cheaper? Let's break it down.

For its part, Amgen is leading with a headline-grabbing cut. The company plans to offer an 80% discount on Amjevita, a medication used to treat conditions like rheumatoid arthritis, psoriasis, and ulcerative colitis. The math is pretty straightforward: a drug originally priced at $1,484 will be available for $299 through the TrumpRx portal. Not too shabby. Amgen also plans to list its drugs Aimovig and Repatha, offering discounts around 62%.

Over at GSK, the discounts are also significant, just structured a bit differently. The company will offer a 55% discount on Incruse, a medication for chronic obstructive pulmonary disease (COPD), pricing it at $159. GSK also plans to list Arnuity, Relenza, and Anoro, with discounts ranging from 10% to 51%.

When reached for comment by MarketDash, representatives for Amgen and GSK did not immediately respond. So, for now, we're going on the report.

TrumpRx: A Quick Refresher on How It Works

If you're just catching up, here's the deal with TrumpRx. President Donald Trump announced the website, TrumpRx.gov, earlier this year. He was joined by the Administrator of the Centers for Medicare & Medicaid Services, Mehmet Oz, and Airbnb co-founder Joe Gebbia. The core idea is pretty simple: it's a portal that lets consumers search for discounted drug prices and print coupons.

It's important to understand what the site is not. It doesn't sell medicines directly. You can't click "add to cart" and have pills shipped to your door. Instead, you search for your medication, compare the discounted price listed, and print a coupon. You then take that coupon to your pharmacy or to the manufacturer's website to redeem the discount. It's a price comparison and coupon-clipping service, but for prescription drugs.

The platform launched with 40 medicines from companies including AstraZeneca PLC (AZN), Eli Lilly And Co. (LLY), EMD Serono, Novo Nordisk (NVO), and Pfizer Inc. (PFE). The report notes that these companies, along with the new additions, have agreed to most-favored-nation (MFN) pricing amid pressure from the Trump administration and potential tariff threats. MFN pricing is a policy approach aimed at tying U.S. drug prices to the lower prices paid in other countries.

The Great Drug Price Debate: Innovation vs. Affordability

Whenever a new player enters the drug pricing fray, the experts line up on either side. This initiative is no different.

On one side, you have the traditional pharmaceutical industry view. Stephen Ubl, CEO of The Pharmaceutical Research and Manufacturers of America (PhRMA), told Fox Business that government-imposed MFN policies could backfire. His argument is a familiar one: such policies could hurt U.S. competitiveness, reduce funding for critical research and development, slow medical innovation, and increase reliance on China for drug manufacturing. He also contends it doesn't address insurance practices that often drive up patient costs at the pharmacy counter.

On the other side, you have voices arguing that the status quo is broken and any effort to lower costs is worth trying. Earlier this month, Costplusdrugs.com CEO Mark Cuban came to the defense of TrumpRx. Cuban, who runs his own online pharmacy focused on transparent, low-cost generics, urged patience.

"Give them a chance," Cuban said, emphasizing the urgency of making healthcare accessible. "Anything that opens the door for lower price medications I'm a fan of."

It's a classic tension in healthcare economics: the need to fund tomorrow's cures versus the very real need for people to afford today's medicines. Initiatives like TrumpRx are trying to navigate that space, offering direct consumer discounts on a selection of brand-name drugs. Whether it's a meaningful step toward systemic change or just a well-publicized coupon program is part of the debate. For patients needing Amjevita or Incruse, an 80% or 55% discount is a very tangible development, regardless of the larger policy arguments.